Bayer's

"We'll stay with the three strategic groups as long as they are competitive in their particular areas," Dekkers said, referring to Bayer's MaterialScience, HealthCare and CropScience divisions.

Reuters: Top News 2011

"The fast-track status is definitely positive news in that it will accelerate the approval process for one of Bayer's most important pipeline assets," said analyst Sebastian Frericks of Metzler Equities.

Bayer Prostate Drug Gets a Boost Sten Stovall 2011

Bayer's pharmaceuticals unit did poorly in recent quarters and analysts didn't expect much improvement for the second quarter, due in particular to continuing generic pressure for the YAZ family of oral contraceptives in the U.S, as well as multiple sclerosis drug Betaseron.

Bayer Delivers a Mixed Bag Natascha Divac 2011

The two drugs are Bayer's most important sales drivers.

Bayer Delivers a Mixed Bag Natascha Divac 2011

Bayer's second-quarter net profit rose 41% to €747 million, while sales rose only 5.4% to €9.25 billion.

Bayer Delivers a Mixed Bag Natascha Divac 2011

Encouraging studies on Alpharadin and two other potential blockbuster drugs—eye-disease treatment Eylea or VEGF Trap-Eye and blood thinner Xarelto—have recently fanned enthusiasm for Bayer's pharmaceutical business.

Bayer Prostate Drug Gets a Boost Sten Stovall 2011

Bayer's pharmaceuticals unit, which continues to suffer due to health-system reforms and generic competition for the YAZ family of oral contraceptives in the U.S., recorded a sales increase of only 4.7% to €2.65 billion.

Bayer Raises Forecast Natascha Divac 2011

News that Alpharadin won FDA fast-track status—which accelerates a drug's approval process by around six months—reminded investors of Bayer's promising drug pipeline and generated strong demand for Bayer shares, sending them up more than 3% in morning business.

Bayer Prostate Drug Gets a Boost Sten Stovall 2011

"We are excited that Alpharadin has achieved this important milestone and recognize this fast-track designation as an important step in the overall development of Alpharadin, particularly for those patients in need of treatment," Bayer's head of global drug development Kemal Malik said in a statement.

Bayer Prostate Drug Gets a Boost Sten Stovall 2011

• In August 2010 EPA announced that Bayer's production of the neurotoxic pesticide aldicarb would end by December 31, 2014.

Donald Carr: Taxpayers Funding Pro-Pesticide PR Campaign Donald Carr 2010